Statera Biopharma, Inc. (STAB) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerStatera Biopharma, Inc. (STAB) trades at $0.0001. Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for autoimmune diseases, cancers, and emerging viruses. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for STAB: STAB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Statera Biopharma, Inc. (STAB) Healthcare & Pipeline Overview
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for autoimmune diseases, cancers, and emerging viruses. Their proprietary platform aims to rebalance the body's immune system and restore homeostasis. The company's pipeline includes programs targeting Crohn's disease, hematology, pancreatic cancer, and COVID-19, positioning it within the competitive biotechnology landscape.
What Is the Investment Thesis for STAB?
Statera BioPharma, Inc. presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. The company's proprietary platform targeting immune homeostasis offers potential for treating a wide range of diseases, including autoimmune disorders, cancers, and emerging viruses. Key value drivers include the successful advancement of its clinical programs, particularly STAT-201 for Crohn's disease and STAT-401 for pancreatic cancer. However, the company faces significant risks, including the uncertainty of clinical trial outcomes, regulatory hurdles, and the need for substantial additional funding. With a market capitalization of $0.00B and negative P/E ratio, the company's valuation is highly dependent on future clinical and regulatory milestones. Positive results from ongoing clinical trials could serve as major catalysts, while setbacks could negatively impact the stock. The company's beta of -4.78 suggests high volatility and a negative correlation with the market.
Based on FMP financials and quantitative analysis
STAB Key Highlights
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies.
- The company's pipeline includes programs targeting Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205).
- Statera BioPharma's proprietary platform is designed to rebalance the body's immune system and restore homeostasis.
- The company changed its name from Cytocom, Inc. in September 2021.
- Statera BioPharma has a market capitalization of $0.00B and operates with 46 employees.
Who Are STAB's Competitors?
STAB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | 0.00% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $16.91 | -1.00% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | -0.05% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | 0.00% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.84 | +2.28% | $206M | 67 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.70 | -0.04% | $218M | 73 5-pillar |
| NAGE Niagen Bioscience Inc | $2.75 | -1.29% | $222M | 68 5-pillar |
| QTTB Q32 Bio Inc. | $8.02 | -2.55% | $245M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are STAB's Key Strengths?
Proprietary platform technology.
- Diverse pipeline of immunotherapies.
- Experienced management team.
- Focus on unmet medical needs.
What Are STAB's Weaknesses?
Clinical-stage company with no approved products.
- Dependence on successful clinical trial outcomes.
- Limited financial resources.
- High cash burn rate.
What Are the Key Risks for STAB?
Financial-distress signal — its Altman Z-Score of -22.79 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures for any of the company's programs.
- Regulatory setbacks or delays in approval processes.
- Competition from other biotechnology companies.
- Inability to secure additional funding to support operations.
- Intellectual property disputes or challenges to patent protection.
What Are STAB's Competitive Advantages?
- Proprietary Platform: Statera BioPharma's unique platform for rebalancing the immune system provides a competitive advantage.
- Patent Protection: Patents on its therapies and platform technology create barriers to entry.
- Clinical Data: Positive clinical trial data can create a strong competitive advantage.
- Experienced Team: A team with expertise in immunology and drug development.
What Does STAB Do?
Statera BioPharma, Inc., formerly known as Cytocom, Inc., is a clinical-stage biopharmaceutical company founded with the mission of developing novel immunotherapies. The company changed its name in September 2021 to reflect its focus on rebalancing the body's immune system. Statera BioPharma operates from its headquarters in Fort Collins, Colorado, and is dedicated to creating therapies that directly elicit antigen-specific killer T-cells and antibodies within patients. The company's core technology platform is designed to restore immune homeostasis, addressing autoimmune, inflammatory, and infectious diseases, as well as cancers. Statera BioPharma's pipeline includes clinical programs targeting a range of conditions, including Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205). The company is also expanding its research and development efforts into fibromyalgia and multiple sclerosis, demonstrating its commitment to addressing unmet medical needs in various therapeutic areas. Statera BioPharma's approach centers on modulating the immune system to fight diseases, differentiating it from traditional pharmaceutical approaches that often focus on symptom management.
What Products and Services Does STAB Offer?
- Develops novel immunotherapies targeting autoimmune diseases.
- Creates therapies for neutropenia/anemia.
- Researches treatments for emerging viruses.
- Develops immunotherapies for various cancers.
- Utilizes a proprietary platform to rebalance the body's immune system.
- Aims to restore homeostasis through immune modulation.
- Conducts clinical programs for Crohn's disease, hematology, pancreatic cancer, and COVID-19.
- Expanding research into fibromyalgia and multiple sclerosis.
How Does STAB Make Money?
- Develops and patents novel immunotherapies.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its therapies.
- Seeks regulatory approval from agencies like the FDA.
- Out-licenses or commercializes approved therapies.
What Industry Does STAB Operate In?
Statera BioPharma operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. Statera BioPharma's focus on immunotherapies aligns with a major trend in the industry, as these therapies have shown promise in treating various diseases, including cancer and autoimmune disorders. The company competes with other biotechnology firms, such as Bloomage Biotechnology Inc (BLMS), Bionomics Limited (BTAX), Better Therapeutics, Inc. (BTTX), ERGO and Evelo Biosciences, Inc. (EVLO), all vying for market share in the development of novel therapeutics.
Who Are STAB's Key Customers?
- Patients suffering from autoimmune diseases.
- Patients with cancer.
- Individuals affected by emerging viruses.
- Healthcare providers and hospitals.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Statera Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Fort Collins, US. The company is led by CEO Blake Hawley. STAB has traded publicly since 2021.
Financial Health
Statera Biopharma, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -22.79 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 11 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
STAB Financials
STAB Latest News
-
Circle Stock Spikes As Binance Takes $100 Million Slice
Investor's Business Daily · Sep 22, 2026
-
How SoFi Is Turning Its Consumer App Into A Stablecoin Proving Ground
Investor's Business Daily · Sep 22, 2026
STAB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for STAB.
Price Targets
Wall Street price target analysis for STAB.
STAB MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for STAB; grades run from A+ (80-100) to F (below 30).
Leadership: Blake Hawley
CEO
Blake Hawley serves as the Chief Executive Officer of Statera Biopharma, Inc. His leadership is pivotal in guiding the company's strategic direction and overseeing its operations. With experience in the biotechnology sector, Hawley is responsible for driving the development of Statera's innovative immunotherapies and expanding its pipeline of clinical programs. His expertise in corporate management and biotechnology is crucial for navigating the complexities of the pharmaceutical industry and achieving the company's goals.
Track Record: Under Blake Hawley's leadership, Statera Biopharma has focused on advancing its clinical programs, including STAT-201 for Crohn's disease and STAT-401 for pancreatic cancer. He has overseen the company's efforts to expand its research and development into new therapeutic areas, such as fibromyalgia and multiple sclerosis. Hawley is also responsible for securing funding and establishing strategic partnerships to support the company's growth.
STAB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Statera Biopharma may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for lack of transparency and liquidity.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The lack of comprehensive financial reporting increases the risk of investing in Statera Biopharma.
- Low Liquidity: The low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Potential for Fraud: The OTC Other tier has a higher risk of fraudulent activity due to the lack of regulatory oversight.
- Volatility: OTC stocks are often more volatile than those listed on major exchanges.
- Limited Information: Information about Statera Biopharma may be scarce and unreliable.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Research the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Established Business Operations: Statera Biopharma has been in operation since before 2021, suggesting some degree of business establishment.
- Clinical Programs: The company has ongoing clinical programs, indicating a commitment to research and development.
- Experienced Management: The presence of a CEO suggests a structured management team.
- Name Change: The company changed its name in 2021, which could indicate a strategic shift or rebranding effort.
- Focus on Immunotherapies: The focus on immunotherapies aligns with a growing trend in the biotechnology industry.
STAB Healthcare Stock FAQ
What do analysts say about STAB stock?
As of March 16, 2026, there is no available analyst coverage or consensus on Statera Biopharma, Inc. (STAB) stock. Given the company's clinical-stage status and OTC listing, it may not be widely followed by analysts.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than major exchange data.